Associate Professor
The University of Tokyo
Tokyo, Tokyo, Japan
Dr. Cabral is an Associate Professor in the Department of Bioengineering, The University of Tokyo. His major research interests relate to the development of nanomedicines against intractable diseases. Some of his nanomedicines loading anticancer drugs have reached human clinical studies, where they showed improved patient survival and safety. His work has also provided breakthroughs in understanding nanomedicine design for tumor-targeted therapy. Recently, Dr. Cabral has been focusing on the development of innovative nanomedicines for proteins, nucleic acids and ribonucleoprotein complexes, such as Cas9/sgRNA, toward the development of next generation therapeutics. Based on the promising results of these projects, he has spin out two companies in 2021 (Red Arrow Therapeutics) and 2022 (Theta Therapeutics). Dr. Cabral has published more than 150 papers (h-index: 58) in high impact factor journals, such as Nature Nanotechnology, Nature Biomedical Engineering, etc. Moreover, he has filed more than 30 patents. He has been recipient of several awards, including the 2022 Innovation Bloom Award from Takeda Pharmaceuticals and the Dean’s Award on Research 2024 from The University of Tokyo. Dr. Cabral serves on the editorial board of Journal of Controlled Release, STAM, Nanomaterials, Frontiers in Oncology and MedComm, and in the advisory board of Macromolecular Bioscience.
Disclosure information not submitted.
Wednesday, July 10, 2024
2:30 PM – 4:30 PM CET
